There are 594 resources available
The TNM stage classification of thymic tumors replacing Masaoka stage system: Old habits die hard
Presenter: Edith Marom
Session: Thymic epithelial tumours: What is new in a multidisciplinary approach
Resources:
Slides
Webcast
cfDNA for targeted therapies: Current position and future developments
Presenter: Thomas John
Session: Above RECIST: A new role for MRD and cfDNA in tumour assessment
Resources:
Slides
Webcast
Thymoma and thymic carcinoma: Different surgical management strategies?
Presenter: Enrico Ruffini
Session: Thymic epithelial tumours: What is new in a multidisciplinary approach
Resources:
Slides
Webcast
Update on systemic therapy in thymic epithelial tumors
Presenter: Nicolas Girard
Session: Thymic epithelial tumours: What is new in a multidisciplinary approach
Resources:
Slides
Webcast
Has MRD detection a role for guiding treatment adaptation in non-oncogene addicted early NSCLC?
Presenter: Atocha Romero
Session: Above RECIST: A new role for MRD and cfDNA in tumour assessment
Resources:
Slides
Webcast
Postoperative radiotherapy in thymic tumors: New indications after the TNM stage classification
Presenter: Andreas Rimner
Session: Thymic epithelial tumours: What is new in a multidisciplinary approach
Resources:
Slides
Webcast
Is liquid biopsy a tool for detecting early relapse in lung cancer patients?
Presenter: Heather Wakelee
Session: Above RECIST: A new role for MRD and cfDNA in tumour assessment
Resources:
Slides
Webcast
Q&A and discussion
Session: Thymic epithelial tumours: What is new in a multidisciplinary approach
Resources:
Webcast
Q&A and discussion
Session: Above RECIST: A new role for MRD and cfDNA in tumour assessment
Resources:
Webcast
Definiton of "borderline resectability" and surgical approach
Presenter: Paula Ugalde
Session: Borderline resectable NSCLC: What is the best approach?
Resources:
Slides
Webcast